Literature DB >> 31424101

Effects of sympathetic modulation in metabolic disease.

Revathy Carnagarin1, Gavin W Lambert2,3, Marcio G Kiuchi1, Janis M Nolde1, Vance B Matthews1, Nina Eikelis2,3, Elisabeth A Lambert2,3, Markus P Schlaich1,4,5.   

Abstract

Sympathetic overdrive contributes to the derangement of glucose metabolism evident in clinical conditions, such as obesity, metabolic syndrome, type 2 diabetes, obstructive sleep apnea, and others. Targeting the sympathetic nervous system directly therefore appears as an attractive therapeutic approach to restore impaired glucose metabolism. Indeed, lifestyle interventions, including healthier diets and exercise, have been shown to exert their beneficial effects at least in part by reducing sympathetic nervous system activity. Pharmacologic inhibition of exaggerated central sympathetic outflow has also been demonstrated to beneficially impact on body weight and glucose and lipid metabolism. More recently, catheter-based renal denervation, an intervention applied predominantly to lower elevated blood pressure in patients with resistant hypertension, revealed salutary effects on glucose metabolism. Here, we review the mechanisms that contribute to the beneficial effects of targeting the sympathetic nervous system directly and discuss how these approaches may best be embedded in routine clinical practice.
© 2019 New York Academy of Sciences.

Entities:  

Keywords:  glucose metabolism; hypertension; metabolic diseases; norepinephrine; renal denervation; sympathetic nervous system

Mesh:

Substances:

Year:  2019        PMID: 31424101     DOI: 10.1111/nyas.14217

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

Review 1.  Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications.

Authors:  Paul Valensi
Journal:  Cardiovasc Diabetol       Date:  2021-08-19       Impact factor: 9.951

2.  FGF19 in the Hindbrain Lowers Blood Glucose and Alters Excitability of Vagal Motor Neurons in Hyperglycemic Mice.

Authors:  Jordan B Wean; Bret N Smith
Journal:  Endocrinology       Date:  2021-04-01       Impact factor: 4.736

3.  Potential Role of Autonomic Dysfunction in Covid-19 Morbidity and Mortality.

Authors:  Rodrigo Del Rio; Noah J Marcus; Nibaldo C Inestrosa
Journal:  Front Physiol       Date:  2020-10-16       Impact factor: 4.566

4.  Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model.

Authors:  Márcio Galindo Kiuchi; Kavitha Ganesan; John Keating; Revathy Carnagarin; Vance B Matthews; Lakshini Y Herat; Gerard Goh; Leon Adams; Markus P Schlaich
Journal:  Clin Res Cardiol       Date:  2021-02-26       Impact factor: 5.460

Review 5.  How COVID-19 can cause autonomic dysfunctions and postural orthostatic syndrome? A Review of mechanisms and evidence.

Authors:  Mehran Hassani; Ali Fathi Jouzdani; Sara Motarjem; Akram Ranjbar; Nakisa Khansari
Journal:  Neurol Clin Neurosci       Date:  2021-10-26

Review 6.  Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.

Authors:  Lakshini Y Herat; Jennifer Matthews; Omar Azzam; Markus P Schlaich; Vance B Matthews
Journal:  Curr Hypertens Rep       Date:  2022-03-02       Impact factor: 5.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.